Quick Cimzia launch overjoys UCB

UCB Pharma was delirious with glee when it managed to launch its new TNF inhibitor Cimzia for Crohn's disease just 48 hours after the FDA gave its blessing. As In Vivo notes, the joy is understandable: The agency's approval surprised skeptics and boosted shares by 20 percent immediately.

But the quick launch is significant for other reasons, too. Though they've become routine, it wasn't so long ago that the FDA was a mysterious, opaque agency, a sort of oracle from which approvals or denials might issue at any time. Then came user fees and deadlines, allowing drugmakers to prep their launches as the agency's action date approached, saving valuable patent-coverage time. Now, though, the understaffed agency has started missing more deadlines, and, infected with excess caution, second-guessing itself. So predictability is starting to suffer--and so might drugmakers' ability to plan ahead.

Not to mention new regulatory requirements, which dogged Cimzia through the approval process. But we'll let In Vivo tell the rest of that story.

- read the blog item

Related Articles:
UCB CEO plots strategy following Cimzia approval
FDA shocks UCB investors with Cimzia trial demand
Late-stage Cimzia trial for RA hits endpoints
UCB submits BLA for Cimzia

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.